Wellthy Therapeutics Acquired

Delivers evidence-backed digital therapeutics that improve chronic-disease outcomes for enterprise partners' end patients.

App acts as a personal health coach using clinical data and patient habits, with a chatbot (Carey) for real-time engagement.

Disease-agnostic, modular platform certified FDA 21 CFR Part 820/11, HIPAA, plus EU MDR Class 1, ISO 13485/27001/27701, IEC 62304 and GDPR.

Platform impact demonstrated at scale prior to its US regulatory certification.

Active therapeutic indications spanning hypertension, dyslipidemia, ischemic heart disease, heart failure, type II diabetes and chronic kidney disease.

B2B2C enterprise customers that embed Wellthy's platform to reach patients.

Patients log meals, track blood sugar, monitor medicines, and interact with chatbot Carey; gamification via badges.

Reaches patients indirectly through enterprise partners rather than direct-to-consumer.

Platform made available through doctors' clinics or co-packaged with partner pharma products.

Regulatory certifications underpin the ability to sell into US and EU-regulated healthcare enterprises.

Cipla subsidiary Goldencross Pharma took an 11.71% equity stake and the companies partnered on combined drug + digital therapy for diabetes and cardiovascular disease.

Partnered to bundle an AI-based digital coaching solution with Roche's Accu-Chek Active blood glucose meter.

Selected for Bayer's G4A digital health partnership program; the only South Asian company in its Berlin cohort.

Monetizes by working with medical insurers, clinics and the pharma industry rather than charging patients directly.

Revenue from bundling the digital therapeutic with a partner's branded drug/device (e.g. Cipla).

Enterprise customers use the platform for patient identification and therapy management, reducing cost of care and claims.